β受体阻滞剂用于可卡因相关胸痛结局的荟萃分析
该系统评价与荟萃分析检索MEDLINE和EMBASE至2016年9月,纳入5项比较β受体阻滞剂与不使用β受体阻滞剂的可卡因相关胸痛研究,共1794例受试者。主要结局非致死性心肌梗死无显著差异(OR 1.36,95%CI 0.68-2.75;p=0.39),全因死亡也无显著差异(OR 0.68,95%CI 0.26-1.79;p=0.43)。结论认为β受体阻滞剂使用似乎不增加心肌梗死或全因死亡风险。
要点
- 可卡因相关胸痛患者使用β受体阻滞剂与不使用者相比,非致死性心肌梗死风险无显著差异(OR 1.36,95%CI 0.68-2.75;p=0.39)。
- 可卡因相关胸痛患者使用β受体阻滞剂与不使用者相比,全因死亡风险无显著差异(OR 0.68,95%CI 0.26-1.79;p=0.43)。
- 共纳入5项研究、1794例受试者,采用随机效应模型进行定量合成,异质性用Q和I2统计量评估。
- 作者结论:在表现为急性胸痛且潜在可卡因使用的患者中,β受体阻滞剂使用似乎不增加心肌梗死或全因死亡风险。
适用人群与场景
- 表现为急性胸痛且潜在可卡因使用的患者(可卡因相关胸痛,CACP)。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析;纳入5项研究,共1794例受试者。
- 干预与对照:β受体阻滞剂使用 vs 不使用β受体阻滞剂。
- 主要结局非致死性心肌梗死:OR 1.36(95%CI 0.68-2.75;p=0.39),两组无显著差异。
- 全因死亡:OR 0.68(95%CI 0.26-1.79;p=0.43),两组无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在表现为急性胸痛且潜在可卡因使用的患者中,β受体阻滞剂使用似乎不增加心肌梗死或全因死亡风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Beta blockers (β-blockers) remain a standard therapy in the early treatment of acute coronary syndromes. However, β-blocker therapy in patients with cocaine-associated chest pain (CACP) continues to be an area of debate due to the potential risk of unopposed α-adrenergic stimulation and coronary vasospasm. Therefore, we performed a systematic review and meta-analysis of available studies to compare outcomes of β-blocker versus no β-blocker use among patients with CACP.
METHODS: We searched the MEDLINE and EMBASE databases through September 2016 using the keywords 'beta blocker', 'cocaine' and commonly used β-blockers ('atenolol', 'bisoprolol', 'carvedilol', 'esmolol', 'metoprolol' and 'propranolol') to identify studies evaluating β-blocker use among patients with CACP. We specifically focused on studies comparing outcomes between β-blocker versus no β-blocker usage in patients with CACP. Studies without a comparison between β-blocker and no β-blocker use were excluded. Outcomes of interest included non-fatal myocardial infarction (MI) and all-cause mortality. Quantitative data synthesis was performed using a random-effects model and heterogeneity was assessed using Q and I2statistics.
RESULTS: A total of five studies evaluating 1794 subjects were included. Overall, there was no significant difference on MI in patients with CACP on β-blocker versus no β-blocker (OR 1.36, 95% CI 0.68 to 2.75; p=0.39). Similarly, there was no significant difference in all-cause mortality in patients on β-blocker versus no β-blocker (OR 0.68, 95% CI 0.26 to 1.79; p=0.43).
CONCLUSIONS: In patients presenting with acute chest pain and underlying cocaine, β-blocker use does not appear to be associated with an increased risk of MI or all-cause mortality.
参考来源
- Pham D, Addison D, Kayani W, et al. Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis. Emerg Med J. 2018. PMID: 29921621. doi:10.1136/emermed-2017-207065
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。